AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22382382 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive peri-stent vascular remodeling (PPVR)
Number of subjects: 226
Study 22382382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discontinuation of dual antiplatelet therapy (DAPT)
Number of subjects: 226
Study 22382382 — intervention group
Group type: EXPERIMENTAL
Intervention: Late acquired stent malapposition (LASM)
Number of subjects: 226
Study 22382382 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent length
Number of subjects: 226
Study 20842042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) with transdermal contraceptive patch (ethinyl estradiol and norelgestromin)
Number of subjects: 32
Study 20842042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) with oral contraceptive pill (ethinyl estradiol and norethindrone)
Number of subjects: 32
Study 20842042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) with transdermal contraceptive patch
Number of subjects: 32
Study 18375093 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine 1mg/kg + ephedrine 70 microg/kg (Group I)
Number of subjects: 80
Study 18375093 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg/kg + ephedrine 70 microg/kg (Group II)
Number of subjects: 80
Study 18375093 — intervention group
Group type: COMPARATOR
Intervention: succinylcholine 1mg/kg + 0.9% saline (Group III)
Number of subjects: 80
Study 18375093 — intervention group
Group type: COMPARATOR
Intervention: rocuronium 0.6 mg/kg + 0.9% saline (Group IV)
Number of subjects: 80
Study 16909301 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon graft (PT tendon)
Number of subjects: 75
Study 16909301 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 strand hamstring graft
Number of subjects: 75
Study 16909301 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hamstring plus extraarticular plasty
Number of subjects: 75
Study 16909301 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar tendon graft
Number of subjects: 75
Study 16909301 — intervention group
Group type: COMPARATOR
Intervention: Four-strand hamstring group
Number of subjects: 75
Study 14670701 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound stimuli with element heterogeneity
Number of subjects: 0
Study 14670701 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound stimuli with element homogeneity
Number of subjects: 0
Study 10997878 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 86
Study 10997878 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 86
Study 8667273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoro Core
Number of subjects: 54
Study 8667273 — intervention group
Group type: EXPERIMENTAL
Intervention: VariGlass VLC
Number of subjects: 54
Study 8667273 — intervention group
Group type: COMPARATOR
Intervention: Miracle Mix
Number of subjects: 54
Study 8667273 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycling
Number of subjects: 54
Study 1730278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy MOCCA (vincristine, cyclophosphamide, lomustine, melphalan, methylprednisolone)
Number of subjects: 80
Study 1730278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy MOCCA
Number of subjects: 80
Study 6144625 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms per hr after a bolus of 50 micrograms)
Number of subjects: 61
Study 6144625 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin (0.4 units per min)
Number of subjects: 61
Study 30328654 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D (Cardiac Resynchronization Therapy with a defibrillator)
Number of subjects: 1106
Study 30328654 — intervention group
Group type: COMPARATOR
Intervention: ICD (Implantable Cardioverter Defibrillator)
Number of subjects: 1106
Study 29802791 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 279
Study 29802791 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + reduced-dose calcineurin-inhibitor
Number of subjects: 279
Study 29802791 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 279
Study 26374849 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3444
Study 24630536 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐ARD score (0‐8, 9‐23, 24‐45)
Number of subjects: 309
Study 22052627 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus low-level laser therapy (4 J/cm(2) at each point over a maximum of ten painful points for total 5 min duration)
Number of subjects: 50
Study 22052627 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 50
Study 22052627 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus low-level laser therapy
Number of subjects: 50
Study 19864958 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and Indapamide (active treatment)
Number of subjects: 6105
Study 19864958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6105
Study 17920465 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-free navigation (group A)
Number of subjects: 467
Study 17920465 — intervention group
Group type: COMPARATOR
Intervention: Optimized conventional technique (group B)
Number of subjects: 467
Study 17920465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 467
Study 16822136 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12792664 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (850-882 mg EPA and DHA as concentrated ethylesters)
Number of subjects: 300
Study 12792664 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (1 g)
Number of subjects: 300
Study 12792664 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs with statins
Number of subjects: 300
Study 12792664 — intervention group
Group type: COMPARATOR
Intervention: Corn oil with statins
Number of subjects: 300
Study 10926918 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Number of subjects: 0
Study 8773822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0
Study 8773822 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 1611115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intron A at 10 MU/instillation
Number of subjects: 67
Study 1611115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intron A at 10 MU and mitomycin C (MMC) at 20 mg/instillation
Number of subjects: 67
Study 1611115 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC) at 20 mg/instillation
Number of subjects: 67
Study 6377568 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose streptokinase (100,000 U/h)
Number of subjects: 80
Study 6377568 — intervention group
Group type: COMPARATOR
Intervention: Low-dose streptokinase (approx 10,000 U/h) with low-dose heparin
Number of subjects: 80
Study 30409926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 66
Study 30409926 — intervention group
Group type: COMPARATOR
Intervention: Amorolfine 0.25% cream
Number of subjects: 66
Study 30409926 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 66
Study 29092994 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 501
Study 25090010 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour psycho-education session combined with bi-weekly telephone support
Number of subjects: 51
Study 23228403 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous nitric oxide (20 ppm)
Number of subjects: 16
Study 21419391 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIENDS cognitive‐behavioral therapy (CBT) intervention
Number of subjects: 444
Study 21419391 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (story-reading)
Number of subjects: 444
Study 18806645 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered care (PCC)
Number of subjects: 0
Study 18806645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16849680 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori treatment (amoxicillin and omeprazole for 2 weeks)
Number of subjects: 3365
Study 16849680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3365
Study 16849680 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplement (aged garlic extract and steam-distilled garlic oil for 7.3 years)
Number of subjects: 3365
Study 16849680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplement (vitamin C, vitamin E, and selenium for 7.3 years)
Number of subjects: 3365
Study 15238367 — intervention group
Group type: EXPERIMENTAL
Intervention: American ginseng
Number of subjects: 20
Study 15238367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11162751 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (1200 mg/day, q.i.d. regimen)
Number of subjects: 40
Study 11162751 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (800 mg/day, b.i.d. regimen)
Number of subjects: 40
Study 11162751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11162751 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (600 mg/day)
Number of subjects: 40
Study 11162751 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (1200 mg/day)
Number of subjects: 40
Study 11162751 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant AEDs
Number of subjects: 40
Study 11162751 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 40
Study 9112891 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflation pressure of 7.5 mmHg
Number of subjects: 40
Study 9112891 — intervention group
Group type: COMPARATOR
Intervention: Insufflation pressure of 15 mmHg
Number of subjects: 40
Study 1546820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen, 2 mg
Number of subjects: 6
Study 1546820 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine, 1 mg
Number of subjects: 6
Study 1546820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1546820 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate, 10 mg
Number of subjects: 6
Study 3935589 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment by phenoxymethyl penicillin
Number of subjects: 108
Study 3935589 — intervention group
Group type: COMPARATOR
Intervention: Short ampicillin course only on the occasion of an acute otitis media episode
Number of subjects: 108
Study 29314581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored video review (M)
Number of subjects: 23
Study 29314581 — intervention group
Group type: COMPARATOR
Intervention: Independent video review (I)
Number of subjects: 23
Study 29977080 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg
Number of subjects: 0
Study 29977080 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 0
Study 29977080 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 29977080 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 27221800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentors with greater self-efficacy and more previous involvement with youth in their communities
Number of subjects: 0
Study 27221800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentors' previous involvement with youth
Number of subjects: 0
Study 27221800 — intervention group
Group type: COMPARATOR
Intervention: Elevated environmental stress
Number of subjects: 0
Study 27221800 — intervention group
Group type: COMPARATOR
Intervention: Elevated rates of youth behavioral problems
Number of subjects: 0
Study 23274578 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg clopidogrel
Number of subjects: 200
Study 23274578 — intervention group
Group type: COMPARATOR
Intervention: 75 mg clopidogrel
Number of subjects: 200
Study 22921739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (15 min arm and shoulder exercise task)
Number of subjects: 133
Study 22921739 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose Pneumococcal vaccination with exercise
Number of subjects: 133
Study 22921739 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose Pneumococcal vaccination with exercise
Number of subjects: 133
Study 22921739 — intervention group
Group type: COMPARATOR
Intervention: Control (resting quietly)
Number of subjects: 133
Study 20813994 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm coiling
Number of subjects: 413
Study 20813994 — intervention group
Group type: COMPARATOR
Intervention: Aneurysm clipping
Number of subjects: 413
Study 17534605 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine
Number of subjects: 12
Study 17534605 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 12
Study 17534605 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 12
Study 16293154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 12
Study 16293154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12145115 — intervention group
Group type: EXPERIMENTAL
Intervention: 0600 hours
Number of subjects: 14
Study 12145115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 hours
Number of subjects: 14
Study 12145115 — intervention group
Group type: COMPARATOR
Intervention: Exercise protocol
Number of subjects: 14
Study 12145115 — intervention group
Group type: COMPARATOR
Intervention: Before exercise
Number of subjects: 14
Study 10214169 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory therapy
Number of subjects: 1
Study 7891982 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with visual compromise (n = 51)
Number of subjects: 29
Study 7891982 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (20 age-matched control subjects)
Number of subjects: 29
Study 7891982 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unilateral lesions (n = 29)
Number of subjects: 29
Study 7891982 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (20 age-matched control subjects)
Number of subjects: 29
Study 2121551 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2: daily GnRH‐a beginning in the midluteal phase, followed by 150 IU hMG after down regulation
Number of subjects: 114
Study 2121551 — intervention group
Group type: COMPARATOR
Intervention: Protocol 1: 100 mg of clomiphene citrate on days 5 to 9, followed by 150 IU hMG beginning on day 9
Number of subjects: 114
Study 649030 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg domperidon t.i.d. for 4 weeks
Number of subjects: 48
Study 649030 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 48
Study 30926276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant Grifols (FS Grifols)
Number of subjects: 166
Study 30926276 — intervention group
Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 166
Study 30926276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant Grifols (FS Grifols) and Manual Compression (MC)
Number of subjects: 166
Study 29273079 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Structured Physiotherapy with an intra-articular steroid injection
Number of subjects: 500
Study 29273079 — intervention group
Group type: COMPARATOR
Intervention: Manipulation under anaesthesia with a steroid injection
Number of subjects: 500
Study 29273079 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic capsular release followed by manipulation
Number of subjects: 500
Study 27084728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg once daily
Number of subjects: 0
Study 27084728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 1.25 μg once daily
Number of subjects: 0
Study 27084728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 μg once daily
Number of subjects: 0
Study 27084728 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium HandiHaler 18 μg once daily
Number of subjects: 0
Study 24332420 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 2013
Study 24332420 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 2013
Study 24332420 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 2013
Study 24332420 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting Endeavor Sprint stents (ZES-S)
Number of subjects: 2013
Study 21948942 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adalimumab 80 mg at baseline followed by 40 mg every other week for 1 year
Number of subjects: 73
Study 21948942 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infliximab 5 mg/kg
Number of subjects: 73
Study 21948942 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adalimumab
Number of subjects: 73
Study 21948942 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infliximab
Number of subjects: 73
Study 21948942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 73
Study 19323050 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help group program for 16 weeks
Number of subjects: 146
Study 19323050 — intervention group
Group type: COMPARATOR
Intervention: Diabetic services (Control)
Number of subjects: 146
Study 17270002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 250
Study 17270002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 16113029 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine combined with chemotherapy
Number of subjects: 2079
Study 11932879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 57
Study 11932879 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 57
Study 11932879 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (CSA and MTX)
Number of subjects: 57
Study 9474925 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 at a dose of 5 micrograms/kg/day for 7 to 14 days
Number of subjects: 0
Study 9474925 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-11 at a dose of 50 micrograms/kg/day for 14 days
Number of subjects: 0
Study 9474925 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin (TPO)
Number of subjects: 0
Study 7535834 — intervention group
Group type: EXPERIMENTAL
Intervention: Single aural toilet and instillation of medicated ointment
Number of subjects: 0
Study 7535834 — intervention group
Group type: COMPARATOR
Intervention: Regular aural toilet and medicated dressings
Number of subjects: 0
Study 2709485 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent oral polio vaccine (TOPV), 5 doses at intervals of 4 weeks
Number of subjects: 62
Study 2709485 — intervention group
Group type: COMPARATOR
Intervention: Trivalent oral polio vaccine (TOPV), 2 doses
Number of subjects: 62
Study 2709485 — intervention group
Group type: COMPARATOR
Intervention: Trivalent oral polio vaccine (TOPV), 3 doses
Number of subjects: 62
Study 779704 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine hydrochloride (15% to 50% of pretrial dose) combined with metyrosine
Number of subjects: 4
Study 779704 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrosine
Number of subjects: 4
Study 31349690 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygonatum sibiricum (PS) rhizome extract (500 mg/day, n = 40)
Number of subjects: 80
Study 31349690 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study 28848126 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover group in the taxane group
Number of subjects: 618
Study 28848126 — intervention group
Group type: COMPARATOR
Intervention: Protocol-recommended group in the taxane group
Number of subjects: 618
Study 28848126 — intervention group
Group type: COMPARATOR
Intervention: Other chemotherapy group in the taxane group
Number of subjects: 618
Study 28848126 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 group
Number of subjects: 618
Study 26079661 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced oral healthcare
Number of subjects: 400
Study 26079661 — intervention group
Group type: COMPARATOR
Intervention: Usual oral healthcare
Number of subjects: 400
Study 23483541 — intervention group
Group type: EXPERIMENTAL
Intervention: ENB 2.0 (external neck brace)
Number of subjects: 20
Study 23483541 — intervention group
Group type: COMPARATOR
Intervention: ENB 1.0 (previous model of external neck brace)
Number of subjects: 20
Study 21644471 — intervention group
Group type: EXPERIMENTAL
Intervention: C- ROM (Clarithromycin, Rifampicin, Ofloxacin, Minocycline)
Number of subjects: 300
Study 21644471 — intervention group
Group type: COMPARATOR
Intervention: ROM (Rifampicin, Ofloxacin, Minocycline)
Number of subjects: 300
Study 21644471 — intervention group
Group type: EXPERIMENTAL
Intervention: C- ROM
Number of subjects: 300
Study 21644471 — intervention group
Group type: COMPARATOR
Intervention: ROM
Number of subjects: 300
Study 19506839 — intervention group
Group type: COMPARATOR
Intervention: 0.125 mg pramipexole
Number of subjects: 20
Study 19506839 — intervention group
Group type: COMPARATOR
Intervention: 0.1875 mg pramipexole
Number of subjects: 20
Study 19506839 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg/kg pramipexole
Number of subjects: 20
Study 19506839 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg/kg pramipexole
Number of subjects: 20
Study 19506839 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg/kg pramipexole
Number of subjects: 20
Study 19506839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16686721 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg GYKI‐16084
Number of subjects: 63
Study 16686721 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg GYKI‐16084
Number of subjects: 63
Study 16686721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 14977342 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 96